Medical Cannabis Research
As reported in the August, 2014 issue of JAMA Internal Medicine, this research shares an examination of the association between medical cannabis laws and opioid analgesic overdose mortality. Each year after implementation of the law showed that such laws were associated with a lower rate of overdose mortality that generally strengthened over time.
This 2004 study by Ethan Russo, published in the journal Neuroendocrinology, examines the concept of clinical endocannabinoid deficiency and the prospect that it could underlie the pathophysiology of migraine, fibromyalgia, irritable bowel syndrome and other functional conditions alleviated by clinical cannabis.
This study, published in the June 2014 issue of the Journal of Clinical Psychopharmacology, describes more than 100 patients reporting about the therapeutic satisfaction with their pharmaceutical-grade cannabis product. Furthermore, differences in subjective effects among the available strains are investigated.
Published in the British Journal of Cancer in 2006, these scientists reported ‘the first clinical study aimed at assessing cannabinoid antitumoral action, specifically a pilot phase I trial in which nine patients with recurrent glioblastoma multiforme were administered THC intratumoraly. The patients had previously failed standard therapy (surgery and radiotherapy) and had clear evidence of tumour progression’.